The	the	O	O
safety	safety	O	O
and	and	O	O
efficacy	efficacy	O	O
of	of	O	O
combination	combination	O	O
N-butyl-deoxynojirimycin	n-butyl-deoxynojirimycin	O	O
(	(	O	O
SC-48334	sc-48334	O	O
)	)	O	O
and	and	O	O
zidovudine	zidovudine	S_chemical	O
in	in	O	O
patients	patients	O	O
with	with	O	O
HIV-1	hiv-1	O	O
infection	infection	O	S_disease
and	and	O	O
200	200	O	O
-	-	O	O
500	500	O	O
CD4	cd4	O	O
cells/mm3.We	cells/mm3.we	O	O
conducted	conducted	O	O
a	a	O	O
double-blind	double-blind	O	O
,	,	O	O
randomized	randomized	O	O
phase	phase	O	O
II	ii	O	O
study	study	O	O
to	to	O	O
evaluate	evaluate	O	O
the	the	O	O
safety	safety	O	O
and	and	O	O
activity	activity	O	O
of	of	O	O
combination	combination	O	O
therapy	therapy	O	O
with	with	O	O
N-butyl-deoxynojirimycin	n-butyl-deoxynojirimycin	O	O
(	(	O	O
SC-48334	sc-48334	O	O
)	)	O	O
(	(	O	O
an	an	O	O
alpha-glucosidase	alpha-glucosidase	O	O
I	i	O	O
inhibitor	inhibitor	O	O
)	)	O	O
and	and	O	O
zidovudine	zidovudine	S_chemical	O
versus	versus	O	O
zidovudine	zidovudine	S_chemical	O
alone	alone	O	O
.	.	O	O

Patients	patients	O	O
with	with	O	O
200	200	O	O
to	to	O	O
500	500	O	O
CD4	cd4	O	O
cells/mm3	cells/mm3	O	O
who	who	O	O
tolerated	tolerated	O	O
<	<	O	O
or	or	O	O
=	=	O	O
12	12	O	O
weeks	weeks	O	O
of	of	O	O
prior	prior	O	O
zidovudine	zidovudine	S_chemical	O
therapy	therapy	O	O
received	received	O	O
SC-48334	sc-48334	O	O
(	(	O	O
1000	1000	O	O
mg	mg	O	O
every	every	O	O
8	8	O	O
h	h	S_chemical	O
)	)	O	O
and	and	O	O
zidovudine	zidovudine	S_chemical	O
(	(	O	O
100	100	O	O
mg	mg	O	O
every	every	O	O
8	8	O	O
h	h	S_chemical	O
)	)	O	O
or	or	O	O
zidovudine	zidovudine	S_chemical	O
and	and	O	O
placebo	placebo	O	O
.	.	O	O

Sixty	sixty	O	O
patients	patients	O	O
received	received	O	O
combination	combination	O	O
therapy	therapy	O	O
and	and	O	O
58	58	O	O
,	,	O	O
zidovudine	zidovudine	S_chemical	O
and	and	O	O
placebo	placebo	O	O
.	.	O	O

Twenty-three	twenty-three	O	O
patients	patients	O	O
(	(	O	O
38	38	O	O
%	%	O	O
)	)	O	O
and	and	O	O
15	15	O	O
(	(	O	O
26	26	O	O
%	%	O	O
)	)	O	O
,	,	O	O
in	in	O	O
the	the	O	O
combination	combination	O	O
and	and	O	O
zidovudine	zidovudine	S_chemical	O
groups	groups	O	O
,	,	O	O
respectively	respectively	O	O
,	,	O	O
discontinued	discontinued	O	O
therapy	therapy	O	O
(	(	O	O
p	p	O	O
=	=	O	O
0.15	0.15	O	O
)	)	O	O
.	.	O	O

The	the	O	O
mean	mean	O	O
SC-48334	sc-48334	O	O
steady-state	steady-state	O	O
trough	trough	O	O
level	level	O	O
(	(	O	O
4.04	4.04	O	O
+	+	O	O
/-	/-	O	O
0.99	0.99	O	O
micrograms/ml	micrograms/ml	O	O
)	)	O	O
was	was	O	O
below	below	O	O
the	the	O	O
in	in	O	O
vitro	vitro	O	O
inhibitory	inhibitory	O	O
concentration	concentration	O	O
for	for	O	O
human	human	O	O
immunodeficiency	immunodeficiency	O	O
virus	virus	O	O
(	(	O	O
HIV	hiv	O	O
)	)	O	O
.	.	O	O

The	the	O	O
mean	mean	O	O
increase	increase	O	O
in	in	O	O
CD4	cd4	O	O
cells	cells	O	O
at	at	O	O
week	week	O	O
4	4	O	O
was	was	O	O
73.8	73.8	O	O
cells/mm3	cells/mm3	O	O
and	and	O	O
52.4	52.4	O	O
cells/mm3	cells/mm3	O	O
for	for	O	O
the	the	O	O
combination	combination	O	O
and	and	O	O
zidovudine	zidovudine	S_chemical	O
groups	groups	O	O
,	,	O	O
respectively	respectively	O	O
(	(	O	O
p	p	O	O
>	>	O	O
0.36	0.36	O	O
)	)	O	O
.	.	O	O

For	for	O	O
patients	patients	O	O
with	with	O	O
prior	prior	O	O
zidovudine	zidovudine	S_chemical	O
therapy	therapy	O	O
,	,	O	O
the	the	O	O
mean	mean	O	O
change	change	O	O
in	in	O	O
CD4	cd4	O	O
cells	cells	O	O
in	in	O	O
the	the	O	O
combination	combination	O	O
and	and	O	O
zidovudine	zidovudine	S_chemical	O
groups	groups	O	O
was	was	O	O
63.7	63.7	O	O
cells/mm3	cells/mm3	O	O
and	and	O	O
4.9	4.9	O	O
cells/mm3	cells/mm3	O	O
at	at	O	O
week	week	O	O
8	8	O	O
and	and	O	O
6.8	6.8	O	O
cells/mm3	cells/mm3	O	O
and	and	O	O
-45.1	-45.1	O	O
cells/mm3	cells/mm3	O	O
at	at	O	O
week	week	O	O
16	16	O	O
,	,	O	O
respectively	respectively	O	O
.	.	O	O

The	the	O	O
number	number	O	O
of	of	O	O
patients	patients	O	O
with	with	O	O
suppression	suppression	O	O
of	of	O	O
HIV	hiv	O	O
p24	p24	O	O
antigenemia	antigenemia	O	O
in	in	O	O
the	the	O	O
combination	combination	O	O
and	and	O	O
zidovudine	zidovudine	S_chemical	O
groups	groups	O	O
was	was	O	O
six	six	O	O
(	(	O	O
40	40	O	O
%	%	O	O
)	)	O	O
and	and	O	O
two	two	O	O
(	(	O	O
11	11	O	O
%	%	O	O
)	)	O	O
at	at	O	O
week	week	O	O
4	4	O	O
(	(	O	O
p	p	O	O
=	=	O	O
0.10	0.10	O	O
)	)	O	O
and	and	O	O
five	five	O	O
(	(	O	O
45	45	O	O
%	%	O	O
)	)	O	O
and	and	O	O
two	two	O	O
(	(	O	O
14	14	O	O
%	%	O	O
)	)	O	O
at	at	O	O
week	week	O	O
24	24	O	O
(	(	O	O
p	p	O	O
=	=	O	O
0.08	0.08	O	O
)	)	O	O
,	,	O	O
respectively	respectively	O	O
.	.	O	O

Diarrhea	diarrhea	O	S_disease
,	,	O	O
flatulence	flatulence	O	O
,	,	O	O
abdominal	abdominal	O	B_disease
pain	pain	O	S_disease
,	,	O	O
and	and	O	O
weight	weight	O	B_disease
loss	loss	O	I_disease
were	were	O	O
common	common	O	O
for	for	O	O
combination	combination	O	O
recipients.(ABSTRACT	recipients.(abstract	O	O
TRUNCATED	truncated	O	O
AT	at	O	O
250	250	O	O
WORDS	words	O	O
)	)	O	O

